Jaguar Health Inc., through its family company Napo Pharmaceuticals, has announced plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the clinical development program for crofelemer aimed at treating microvillus inclusion disease (MVID), a rare pediatric disorder. Initial proof-of-concept results from an investigator-initiated trial in Abu Dhabi indicated that crofelemer reduced the requirement for total parenteral nutrition in the first participating MVID patient by up to 27%. These findings have been accepted for presentation at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) 2025 Annual Meeting in Chicago. Jaguar Health is supporting ongoing trials in various regions, and the company aims to explore expedited regulatory pathways based on the promising initial results.